GlassScriptPhysician profile
Gregory S Phillips
NPI 1497743413
$6,287.69
in general payments reported to CMS, 2019-2025
47 companies · $968 in 2025
The $968 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $733 · 2020: $484 · 2021: $501 · 2022: $946 · 2023: $1,297 · 2024: $1,360 · 2025: $968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,539 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,539.26 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,056.37 | 2021-2025 | |
| Lilly USA, LLC | $1,001.97 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $613.02 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $594.47 | 2020-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $394.61 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $374.14 | 2019-2025 | |
| Novo Nordisk INC | $235.73 | 2019-2025 | Ozempic, Rybelsus |
| Sumitomo Pharma America, INC. | $214.82 | 2023-2025 | Gemtesa, Myfembree |
| Astellas Pharma US INC | $191.54 | 2019-2024 | Veozah |
| Exeltis, USA INC. | $146.62 | 2021-2023 | Slynd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.67 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $112.06 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $111.68 | 2019-2021 | |
| Axsome Therapeutics, INC. | $76.95 | 2023-2024 | Auvelity |
| Novartis Pharmaceuticals Corporation | $74.95 | 2022-2023 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $68.76 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $66.78 | 2023-2025 | Zoryve, Livalo, Seglentis |
| Bayer Healthcare Pharmaceuticals INC. | $58.24 | 2023-2025 | |
| Exact Sciences Corporation | $48.75 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Curonix LLC | $48.13 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Hologic Sales and Service, LLC | $47.16 | 2024 | Myosure Tissue Removal Device, Novasure |
| Esperion Therapeutics, INC. | $45.27 | 2024-2025 | Nexletol |
| Biohaven Pharmaceutical Holding Company LTD. | $42.29 | 2022 | |
| Verona Pharma, INC. | $36.81 | 2025 | Ohtuvayre |
| Myovant Sciences INC. | $36.60 | 2022 | |
| Antares Pharma, INC. | $35.59 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Shield Therapeutics INC | $32.20 | 2024 | |
| Duchesnay USA Incorporated | $29.70 | 2019 | |
| Tolmar, INC. | $29.20 | 2025 | Jatenzo |
| Inogen, INC. | $28.04 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Avanir Pharmaceuticals, INC. | $23.90 | 2021 | |
| Allergan, INC. | $23.67 | 2019-2020 | |
| Lundbeck LLC | $23.42 | 2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $22.10 | 2023 | Trintellix |
| Abiomed | $19.99 | 2024 | Impella |
| Abbott Laboratories | $19.59 | 2022 | |
| Dexcom, INC. | $17.56 | 2025 | Dexcom G6 Transmitter |
| Tonix Medicines, INC. | $16.59 | 2025 | Tonmya |
| Smith+Nephew, INC. | $15.85 | 2023 | Grafix |
| Otsuka America Pharmaceutical, INC. | $15.32 | 2023 | Rexulti |
| Phathom Pharmaceuticals, INC. | $14.61 | 2024 | Voquezna |
| Sun Pharmaceutical Industries INC. | $14.05 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.68 | 2021 | |
| Biogen, INC. | $12.70 | 2020 | |
| Therapeuticsmd, INC. | $12.37 | 2019 | |
| Evoke Pharma, INC. | $12.21 | 2021 | |
| Merck Sharp & Dohme LLC | $11.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.